Literature DB >> 17610017

2-deoxy-2-[F-18]fluoro-D-glucose accumulation in ovarian carcinoma cell lines.

A M Lutz1, P Ray, J K Willmann, Charles Drescher, S S Gambhir.   

Abstract

PURPOSE: To evaluate 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) accumulation in human ovarian carcinoma cell lines compared with control tumor cell lines known to accumulate FDG. PROCEDURES: FDG accumulation assays were performed in 15 different ovarian carcinoma cell lines at 1, 2, and 3 hours after incubation with 1 microCi of FDG. Results were compared with FDG accumulation in six different control tumor cell lines. 2-deoxy-2-[F-18]fluoro-D-glucose accumulation was expressed as counts per minute (cpm) in cells and normalized to initial cpm in medium and total protein content of cell lysates.
RESULTS: FDG accumulation in all 15 ovarian carcinoma cell lines was equal to or higher than 0.0005 +/- 8.6 10(-5) cpm in cells/cpm in medium/mug protein at all three different time points. In two ovarian carcinoma cell lines (ES-2, poorly differentiated clear cell carcinoma, and OVCAR-3, poorly differentiated papillary adenocarcinoma), FDG accumulation was not statistically, significantly different compared to the control cell line with the highest FDG accumulation (LS 174T human colorectal adenocarcinoma) at two or more time points (P > or = 0.07). In 2 of 15 (13%) ovarian carcinoma cell lines (OVCAR5 epithelial carcinoma and SKOV3 clear cell carcinoma), FDG accumulation was lower than that in the control cell line with the lowest FDG accumulation (HT-29 human colorectal adenocarcinoma) at one or more time points (P < 0.05).
CONCLUSIONS: Most human ovarian carcinoma cell lines showed comparable FDG accumulations with control cell lines known to accumulate FDG. This study lays the foundations for further comparisons with other ovarian cancer cell lines and for other positron emission tomography tracers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17610017     DOI: 10.1007/s11307-007-0105-4

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  28 in total

1.  Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography.

Authors:  D Grab; F Flock; I Stöhr; K Nüssle; A Rieber; S Fenchel; H J Brambs; S N Reske; R Kreienberg
Journal:  Gynecol Oncol       Date:  2000-06       Impact factor: 5.482

2.  The diagnostic value of PET/CT for primary ovarian cancer--a prospective study.

Authors:  Signe Risum; Claus Høgdall; Annika Loft; Anne K Berthelsen; Estrid Høgdall; Lotte Nedergaard; Lene Lundvall; Svend A Engelholm
Journal:  Gynecol Oncol       Date:  2007-01-16       Impact factor: 5.482

3.  Effects of hypoxia on the uptake of tritiated thymidine, L-leucine, L-methionine and FDG in cultured cancer cells.

Authors:  A C Clavo; R L Wahl
Journal:  J Nucl Med       Date:  1996-03       Impact factor: 10.057

4.  Metabolites of 2'-fluoro-2'-deoxy-D-glucose detected by 19F magnetic resonance spectroscopy in vivo predict response of murine RIF-1 tumors to 5-fluorouracil.

Authors:  P M McSheehy; M O Leach; I R Judson; J R Griffiths
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

5.  Tetraphenylphosphonium as a novel molecular probe for imaging tumors.

Authors:  Jung-Jun Min; Sandip Biswal; Christophe Deroose; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2004-04       Impact factor: 10.057

6.  The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro.

Authors:  A Waki; H Kato; R Yano; N Sadato; A Yokoyama; Y Ishii; Y Yonekura; Y Fujibayashi
Journal:  Nucl Med Biol       Date:  1998-10       Impact factor: 2.408

7.  Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors.

Authors:  T C Hamilton; R C Young; W M McKoy; K R Grotzinger; J A Green; E W Chu; J Whang-Peng; A M Rogan; W R Green; R F Ozols
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

8.  Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT.

Authors:  Hedva Lerman; Ur Metser; Dan Grisaru; Ami Fishman; Gennady Lievshitz; Einat Even-Sapir
Journal:  J Nucl Med       Date:  2004-02       Impact factor: 10.057

9.  Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia.

Authors:  A C Clavo; R S Brown; R L Wahl
Journal:  J Nucl Med       Date:  1995-09       Impact factor: 10.057

10.  Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells.

Authors:  B Y Karlan; J Jones; D J Slamon; L D Lagasse
Journal:  Gynecol Oncol       Date:  1994-04       Impact factor: 5.482

View more
  5 in total

1.  The role of dysregulated glucose metabolism in epithelial ovarian cancer.

Authors:  L D Kellenberger; J E Bruin; J Greenaway; N E Campbell; R A Moorehead; A C Holloway; J Petrik
Journal:  J Oncol       Date:  2010-02-17       Impact factor: 4.375

2.  An evaluation of 2-deoxy-2-[18F]fluoro-D-glucose and 3'-deoxy-3'-[18F]-fluorothymidine uptake in human tumor xenograft models.

Authors:  Heather Keen; Bernd Pichler; Damaris Kukuk; Olivier Duchamp; Olivier Raguin; Aoife Shannon; Nichola Whalley; Vivien Jacobs; Juliana Bales; Neill Gingles; Sally-Ann Ricketts; Stephen R Wedge
Journal:  Mol Imaging Biol       Date:  2012-06       Impact factor: 3.488

3.  Melatonin Synergizes the Chemotherapeutic Effect of Cisplatin in Ovarian Cancer Cells Independently of MT1 Melatonin Receptors.

Authors:  Agata Zemła; Irmina Grzegorek; Piotr Dzięgiel; Karolina Jabłońska
Journal:  In Vivo       Date:  2017 Sep-Oct       Impact factor: 2.155

4.  Immuno-PET of epithelial ovarian cancer: harnessing the potential of CA125 for non-invasive imaging.

Authors:  Sai Kiran Sharma; Melinda Wuest; Monica Wang; Darryl Glubrecht; Bonnie Andrais; Suzanne E Lapi; Frank Wuest
Journal:  EJNMMI Res       Date:  2014-11-12       Impact factor: 3.138

5.  Effect of Cerenkov Radiation-Induced Photodynamic Therapy with 18F-FDG in an Intraperitoneal Xenograft Mouse Model of Ovarian Cancer.

Authors:  Yi-An Chen; Jia-Je Li; Syue-Liang Lin; Cheng-Hsiu Lu; Sain-Jhih Chiu; Fong-Shya Jeng; Chi-Wei Chang; Bang-Hung Yang; Ming-Cheng Chang; Chien-Chih Ke; Ren-Shyan Liu
Journal:  Int J Mol Sci       Date:  2021-05-06       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.